ERVEBO Drug Profile

Summary for Tradename: ERVEBO

High Confidence Patents:	1
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for ERVEBO

Recent Clinical Trials for ERVEBO

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Institut National pour la Recherche Biomedicale (INRB)	Phase 3
Institute of Tropical Medicine, Belgium	Phase 3
Méthodologie et Evaluation pour la Recherche clinique et Epidémiologique sur le VIH en Afrique (MEREVA)	Phase 2

See all ERVEBO clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ERVEBO Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ERVEBO Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	ERVEBO	ebola zaire vaccine, live	Injection	125690	8,012,489	2023-07-28	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ERVEBO Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for ERVEBO

Last updated: April 12, 2026

What is ERVEBO?

ERVEBO (Ebola Zaire vaccine, rVSV-ZEBOV-GP) is a recombinant vesicular stomatitis virus vaccine developed for Ebola virus disease. It received FDA approval in December 2019 and is marketed by Merck & Co.[1].

Market Size and Drivers

• The global vaccine market was valued at approximately $50 billion in 2021, with the infectious disease segment growing at a compound annual growth rate (CAGR) of 7.4% (2016-2021).[2]
• Ebola-specific vaccines represent a niche segment within infectious disease vaccines, with limited annual sales to date, primarily driven by epidemic outbreaks and targeted vaccination campaigns.

Key Factors Influencing Market Dynamics

Epidemiological Need: Outbreaks in Central and West Africa trigger demand for ERVEBO. Sporadic cases in the US and Europe stimulate targeted stockpiling but do not sustain high sales long-term.

Regulatory Status:

• FDA approved in 2019.
• WHO prequalified in 2020, facilitating broad procurement in global health initiatives.

Public Sector and Emergency Response:

• Gavi, the Vaccine Alliance, supports stockpiling and distribution in endemic regions.
• WHO's strategic emergency stockpile plans influence procurement cycles.

Competitors and Alternatives:

• No direct licensed competitors for Ebola Zaire vaccine.
• Several candidates in clinical development, such as Zabdeno and Mvabea (Johnson & Johnson), but none have achieved licensure.[3]

Pricing Strategy:

• Varies depending on the buyer and procurement environment.
• Gavi-negotiated prices tend to be below commercial market levels, affecting margins.

Revenue Projections

Historical Sales Data:

• Estimated global sales of ERVEBO remained under $100 million in 2021, primarily driven by outbreak-driven stockpiling[4].

Forecast Scenarios:

Year	Estimated Sales (USD millions)	Assumptions
2022	120 - 150	Increased outbreak responses, expanded immunization in endemic areas
2023	130 - 180	Possible expansion into supplementary indications or booster campaigns
2024	140 - 200	Potential for increased demand due to new outbreak waves

Sales are expected to be highly episodic, tied to outbreak occurrence and vaccination campaigns.

Cost Structure:

• Initial R&D costs estimated at $600 million over a decade.[5]
• Manufacturing costs are relatively high due to cold chain requirements and live-attenuated nature.

Profitability:

• Margins are limited by vaccination program funding constraints.
• Long-term profitability is uncertain absent sustained epidemic activity or expanded indications.

Strategic Considerations

• Merck's stockpile contracts with WHO and Gavi are central to revenue stability.
• Investment in next-generation vaccines or booster formulations could unlock new revenue streams.
• Market entry barriers include rapid emergence of competing vaccines and complex logistics.

Key Takeaways

• ERVEBO remains a niche product with episodic revenue tied to Ebola outbreaks.
• The vaccine's market potential depends on outbreak frequency, global stockpiling policies, and regulatory approvals.
• While current sales are modest, increased global preparedness and outbreak response efforts could gradually boost revenues.
• Competitive landscape is limited but includes emerging candidates that may challenge ERVEBO's dominance.
• Cost and logistics complexities limit scalability and profit margins.

FAQs

1. What factors limit ERVEBO's market expansion?
Ebola outbreaks are unpredictable and infrequent, resulting in episodic demand. Cold chain logistics and high manufacturing costs also restrict scalability.

2. How does outbreak frequency affect ERVEBO's sales?
Sales surge during outbreaks, which prompt stockpiling and vaccination campaigns, but decline significantly between outbreaks.

3. Are there risks that could impact ERVEBO’s future sales?
Yes. Emergence of new Ebola strains, regulatory delays, or competitors developing effective vaccines could reduce market share or demand.

4. What role do global health agencies play in ERVEBO’s revenue?
Organizations like WHO and Gavi purchase vaccines for stockpiles and outbreak responses, providing predictable revenue streams but with variable volumes.

5. What is the long-term outlook for ERVEBO?
Uncertain. Volatility in outbreak activity and evolving vaccine landscape influence future market size and profitability.

---

References

[1] U.S. Food and Drug Administration. (2019). FDA approves vaccine for Ebola virus disease.
[2] Grand View Research. (2022). Vaccine market size, share & trends analysis report.
[3] WHO. (2021). Ebola vaccine development pipeline.
[4] Merck & Co. Annual Report. (2022).
[5] Marketline. (2022). Biologic drug development pipeline and financials.